HBIO
Price
$0.53
Change
+$0.04 (+8.16%)
Updated
Aug 15 closing price
Capitalization
23.56M
81 days until earnings call
MLSS
Price
$0.65
Change
+$0.07 (+12.07%)
Updated
Aug 15 closing price
Capitalization
51.01M
87 days until earnings call
Interact to see
Advertisement

HBIO vs MLSS

Header iconHBIO vs MLSS Comparison
Open Charts HBIO vs MLSSBanner chart's image
Harvard Bioscience
Price$0.53
Change+$0.04 (+8.16%)
Volume$934.06K
Capitalization23.56M
Milestone Scientific
Price$0.65
Change+$0.07 (+12.07%)
Volume$275.29K
Capitalization51.01M
HBIO vs MLSS Comparison Chart in %
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HBIO vs. MLSS commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Hold and MLSS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (HBIO: $0.53 vs. MLSS: $0.65)
Brand notoriety: HBIO and MLSS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HBIO: 94% vs. MLSS: 59%
Market capitalization -- HBIO: $23.56M vs. MLSS: $51.01M
HBIO [@Pharmaceuticals: Other] is valued at $23.56M. MLSS’s [@Pharmaceuticals: Other] market capitalization is $51.01M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $172.16B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $11.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileMLSS’s FA Score has 0 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • MLSS’s FA Score: 0 green, 5 red.
According to our system of comparison, HBIO is a better buy in the long-term than MLSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 5 TA indicator(s) are bullish while MLSS’s TA Score has 5 bullish TA indicator(s).

  • HBIO’s TA Score: 5 bullish, 5 bearish.
  • MLSS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MLSS is a better buy in the short-term than HBIO.

Price Growth

HBIO (@Pharmaceuticals: Other) experienced а +0.23% price change this week, while MLSS (@Pharmaceuticals: Other) price change was +1.64% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.19%. For the same industry, the average monthly price growth was -0.65%, and the average quarterly price growth was +3.82%.

Reported Earning Dates

HBIO is expected to report earnings on Nov 06, 2025.

MLSS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.19% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLSS($51M) has a higher market cap than HBIO($23.6M). MLSS YTD gains are higher at: -32.292 vs. HBIO (-74.929). MLSS has higher annual earnings (EBITDA): -7.15M vs. HBIO (-47.68M). HBIO has more cash in the bank: 5.55M vs. MLSS (2.25M). MLSS has less debt than HBIO: MLSS (319K) vs HBIO (44.6M). HBIO has higher revenues than MLSS: HBIO (91.4M) vs MLSS (8.61M).
HBIOMLSSHBIO / MLSS
Capitalization23.6M51M46%
EBITDA-47.68M-7.15M667%
Gain YTD-74.929-32.292232%
P/E RatioN/AN/A-
Revenue91.4M8.61M1,061%
Total Cash5.55M2.25M247%
Total Debt44.6M319K13,981%
FUNDAMENTALS RATINGS
HBIO vs MLSS: Fundamental Ratings
HBIO
MLSS
OUTLOOK RATING
1..100
1631
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
98
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6091
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLSS's Valuation (98) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

MLSS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

MLSS's SMR Rating (98) in the Medical Specialties industry is in the same range as HBIO (99) in the Biotechnology industry. This means that MLSS’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (60) in the Biotechnology industry is in the same range as MLSS (91) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to MLSS’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for MLSS (100) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than MLSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIOMLSS
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 10 days ago
79%
Declines
ODDS (%)
Bearish Trend 17 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NRXS2.410.04
+1.69%
Neuraxis
PINE14.60-0.06
-0.41%
Alpine Income Property Trust
CARR65.40-0.36
-0.55%
Carrier Global Corp
OGS75.64-0.62
-0.81%
ONE GAS
SLDP5.06-0.31
-5.77%
Solid Power

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+8.09%
IRMD - HBIO
51%
Loosely correlated
+0.33%
SGHT - HBIO
39%
Loosely correlated
-1.18%
A - HBIO
38%
Loosely correlated
+0.28%
TMO - HBIO
35%
Loosely correlated
+0.82%
MTD - HBIO
35%
Loosely correlated
-0.10%
More

MLSS and

Correlation & Price change

A.I.dvisor tells us that MLSS and BLFS have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and BLFS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLSS
1D Price
Change %
MLSS100%
+12.22%
BLFS - MLSS
27%
Poorly correlated
-3.87%
ANGO - MLSS
26%
Poorly correlated
+0.46%
ESTA - MLSS
26%
Poorly correlated
+0.97%
PRE - MLSS
26%
Poorly correlated
-1.17%
HBIO - MLSS
25%
Poorly correlated
+8.09%
More